Teva Pharmaceutical Industries (NYSE:TEVA) Releases Q1 2025 Earnings Guidance

Teva Pharmaceutical Industries (NYSE:TEVA) updated its first quarter 2025 earnings guidance on Friday. The company provided EPS guidance of 0.520-0.520 for the period, compared to the consensus EPS estimate of 0.480. The company issued revenue guidance of $4.0 billion-$4.0 billion, compared to the consensus revenue estimate of $4.0 billion. Teva Pharmaceutical Industries also updated its FY 2025 guidance to 2.350-2.650 EPS.

Teva Pharmaceutical Industries Price Performance

TEVA stock opened at $15.50 on Friday. The business has a 50 day simple moving average of $17.35 and a 200-day simple moving average of $18.14. Teva Pharmaceutical Industries has a twelve month low of $12.51 and a twelve month high of $22.80. The company has a market capitalization of $17.57 billion, a P/E ratio of -10.68, a PEG ratio of 1.44 and a beta of 0.82. The company has a current ratio of 0.98, a quick ratio of 0.75 and a debt-to-equity ratio of 2.97.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its earnings results on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, beating analysts’ consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. As a group, equities analysts anticipate that Teva Pharmaceutical Industries will post 2.5 EPS for the current year.

Wall Street Analysts Forecast Growth

TEVA has been the topic of a number of recent research reports. StockNews.com lowered Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a report on Thursday. UBS Group cut their price objective on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating for the company in a research report on Thursday, January 30th. Piper Sandler raised their price target on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an “overweight” rating in a report on Friday, January 17th. Barclays lowered their target price on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating on the stock in a report on Thursday, January 30th. Finally, Bank of America cut their price target on Teva Pharmaceutical Industries from $23.00 to $20.00 and set a “buy” rating for the company in a research note on Thursday, March 6th. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $23.43.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.